WeChat: 13022869828
Phone: 86-29-89601602
E-mail: sales28@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China

Antitumor Sunitinib Malate Raw material powder

< >

Product Overview:

Sunitinib works by preventing tumor cells from getting the blood and nutrients they need to grow. Clinical trials have shown that the drug can slow the growth rate of gastrointestinal stromal tumors and reduce the size of kidney cell tumors. Sunitinib malate is the first novel targeted drug that can selectively target multiple tyrosine kinase receptors, combining two mechanisms of action: anti-angiogenesis, which interrupts blood supply to tumor cells, and anti-tumor, which directly attacks tumor cells. It represents the advent of a new wave of targeted therapies that can directly attack tumors without the toxic side effects of conventional chemotherapy.

Booking Online

Free trial of samples

Antitumor Sunitinib Malate Raw material powder Attributes

Sunitinib Malate Raw material powder

CAS:341031-54-7

MF:C26H33FN4O7

MW:532.57

EINECS:638-825-9

Specification: 99% min Sunitinib Malate powder

Sample:Sunitinib Malate powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:orange

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Antitumor Sunitinib Malate Raw material powder Details

Sunitinib Malate Powder Usage and Synthesis.

1. Gastrointestinal stromal tumors (GIST) that fail to be treated with imatinib mesylate or are not tolerated.

2. Inoperable advanced renal cell carcinoma (RCC).

3. Treatment of advanced endocrine tumors such as pancreas.

Uses of Sunitinib Malate.

In vitro study of Sunitinib Malate.

Sunitinib is also a potent c-Kit inhibitor with an IC50 of 211nM. Sunitinib is a potent ATP-competitive VEGFR2(Flk1) and PDGFRβ inhibitor with Ki of 9nM and 8nM, respectively, and its action on VEGFR2 and PDGFR is more than 10 times more selective than that on FGFR-1,EGFR,Cdk2,Met,IGFR-1,Abl, and src. Sunitinib acts on serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, inhibiting VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10nM and 10nM, respectively. Sunitinib inhibited the proliferation of VEGF-induced serum starved HUVECs with an IC50 of 40nM, and NIH-3T3 cells induced by PDGF overexpressing PDGFRβ or PDGFRα with IC50 of 39nM and 69nM, respectively. Sunitinib inhibits wild-type FLT3,FLT3-ITD, and FLT3-ASP835 phosphorylation with IC50 of 250nM,50nM, and 30nM, respectively. Sunitinib inhibited MV4; 11 and OC1-AML5 cells proliferated with IC50 of 8nM and 4nM, respectively, and induced apoptosis in a dose-dependent manner

Product Method of Bulk Sunitinib Malate Powder.